Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) May 25, 2010 -- Dallas,

TX: ReportsandReports announce it will carry Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016,Market Research Report in its Store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/allergic-conjunctivitis-drug-pipeline-analysis-and-market-forec/

Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData’s pharmaceutical and healthcare report,” Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies
Scope
The scope of the report includes:
- Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.
- Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos B

MarketResearch     marketresearchreport